Search
01/03/2023
What's New in the 2022 Consensus for Severe Asthma in Adults.
Alvarez-Gutiérrez FJ, Blanco-Aparicio M, Casas-Maldonado F, Plaza V, González-Barcala FJ, Carretero-Gracia JÁ, Castilla-Martínez M, Cisneros C, Diaz-Pérez D, Domingo-Ribas C, Martínez-Moragon E, Muñoz X, Padilla-Galo A, Perpiña-Tordera M, Soto-Campos G. What's New in the 2022 Consensus for Severe Asthma in Adults.. ARCHIVOS DE BRONCONEUMOLOGIA. 2023; 59(3)DOI:10.1016/j.arbres.2022.09.012. PMID:36243640. IF:8.700(Q1/1D).
01/03/2023
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial
Waters, L, Assoumou, L, Gonzalez-Cordon, A, Rusconi, S, Domingo, P, Gompels, M, de Wit, S, Raffi, F, Stephan, C, Masia, M, Rockstroh, J, Katlama, C, Behrens, GMN, Moyle, G, Johnson, M, Fox, J, Stellbrink, HJ, Guaraldi, G, Florence, E, Esser, S, Gatell, JM, Pozniak, A, Martinez, E. Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial. CLINICAL INFECTIOUS DISEASES. 2023; 76(5)DOI:10.1093/cid/ciac827. PMID:36259527. IF:8.200(Q1/1D).
01/03/2023
T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo
Nunez, Y, Garcia-Leon, A, Falgas, A, Serna, N, Sanchez-Garcia, L, Garrido, A, Sierra, J, Gallardo, A, Unzueta, U, Vazquez, E, Villaverde, A, Mangues, R, Casanova, I. T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo. Pharmaceutics. 2023; 15(3)DOI:10.3390/pharmaceutics15030727. PMID:36986589. IF:4.900(Q1/2D).
01/03/2023
Quantitative PCR for the Diagnosis of HCMV Pneumonia in HSCT Recipients and Other Immunocompromised Hosts
Berengua, C, Martino, R. Quantitative PCR for the Diagnosis of HCMV Pneumonia in HSCT Recipients and Other Immunocompromised Hosts. Hemato. 2023; 4(1)DOI:10.3390/hemato4010008. PMID:. IF:(Q/D).